For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 187,402 | |||
| General and administrative expense | 54,246 | |||
| Total operating expenses | 241,648 | |||
| Loss from operations | -241,648 | |||
| Interest income | 22,212 | |||
| Other income (expense), net | -443 | |||
| Net loss before income taxes | -219,879 | |||
| Effective tax rate | 0 | |||
| Net loss | -219,879 | |||
| Net loss attributable to noncontrolling interests | 0 | |||
| Net loss attributable to cullinan | -219,879 | |||
| Basic EPS | -3.36 | |||
| Diluted EPS | -3.36 | |||
| Basic Average Shares | 59,050,000 | |||
| Diluted Average Shares | 59,050,000 | |||
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)